Movement Disorders

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

The company is planning a pivotal trial of blarcamesine in Parkinson disease dementia after submitting results of the phase 2 study to the FDA for regulatory guidance.

Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, discussed the translational potential of DystoniaNet, and its potential to be adjusted for use in additional disease states.

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers explained how preventing social isolation—particularly in the time of COVID-19—can help prevent worsened disease states in patients.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

Advances in wearables and virtual reality present an opportunity to maximize rehabilitative efforts and improve outcomes.

The Cleveland Clinic researcher described the 2-fold potential use for how his predictive Parkinson disease dementia model may be used pending the success of the study.

Kristina Simonyan, MD, PhD, DrMed, and Davide Valeriani, PhD, offered insight into the use of DystoniaNet, which identified the condition with 98.8% accuracy in a matter of 0.36 seconds.

Here's what is coming soon to NeurologyLive.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

The Cleveland Clinic researcher details a study that will use biomarkers to develop a predictive model to identify individuals with Parkinson disease who may develop dementia.